BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 28807490)

  • 1. FABP1 and Hepar expression levels in Barrett's esophagus and associated neoplasia in an Asian population.
    Srivastava S; Kern F; Sharma N; McKeon F; Xian W; Yeoh KG; Ho KY; Teh M
    Dig Liver Dis; 2017 Oct; 49(10):1104-1109. PubMed ID: 28807490
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CEACAM 6, a novel marker for the diagnosis of Barrett's esophagus.
    Sharma N; Srivastava S; Kern F; Xian W; Yeoh KG; Ming T; McKeon F; Ho KY
    Dis Esophagus; 2017 Jul; 30(7):1-5. PubMed ID: 28475729
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression profiles of cancer stem cell markers: CD133, CD44, Musashi-1 and EpCAM in the cardiac mucosa-Barrett's esophagus-early esophageal adenocarcinoma-advanced esophageal adenocarcinoma sequence.
    Mokrowiecka A; Veits L; Falkeis C; Musial J; Kordek R; Lochowski M; Kozak J; Wierzchniewska-Lawska A; Vieth M; Malecka-Panas E
    Pathol Res Pract; 2017 Mar; 213(3):205-209. PubMed ID: 28216140
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunohistochemical analysis of metaplastic non-goblet columnar lined oesophagus shows phenotypic similarities to Barrett's oesophagus: a study in an Asian population.
    Srivastava S; Liew MS; McKeon F; Xian W; Yeoh KG; Ho KY; Teh M
    Dig Liver Dis; 2014 Feb; 46(2):170-5. PubMed ID: 24290871
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of the putative intestinal stem cell marker doublecortin and CaM kinase-like-1 in Barrett's esophagus and esophageal adenocarcinoma.
    Vega KJ; May R; Sureban SM; Lightfoot SA; Qu D; Reed A; Weygant N; Ramanujam R; Souza R; Madhoun M; Whorton J; Anant S; Meltzer SJ; Houchen CW
    J Gastroenterol Hepatol; 2012 Apr; 27(4):773-80. PubMed ID: 21916995
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High Expression of Cathepsin E in Tissues but Not Blood of Patients with Barrett's Esophagus and Adenocarcinoma.
    Fisher OM; Levert-Mignon AJ; Lord SJ; Botelho NK; Freeman AK; Thomas ML; Falkenback D; Wettstein A; Whiteman DC; Bobryshev YV; Lord RV
    Ann Surg Oncol; 2015 Jul; 22(7):2431-8. PubMed ID: 25348778
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased CDX2 and decreased PITX1 homeobox gene expression in Barrett's esophagus and Barrett's-associated adenocarcinoma.
    Lord RV; Brabender J; Wickramasinghe K; DeMeester SR; Holscher A; Schneider PM; Danenberg PV; DeMeester TR
    Surgery; 2005 Nov; 138(5):924-31. PubMed ID: 16291394
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cdx2 as a marker of epithelial intestinal differentiation in the esophagus.
    Phillips RW; Frierson HF; Moskaluk CA
    Am J Surg Pathol; 2003 Nov; 27(11):1442-7. PubMed ID: 14576477
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CDX2 and LI-cadherin expression in esophageal mucosa: use of both markers can facilitate the histologic diagnosis of Barrett's esophagus and carcinoma.
    Weimann A; Zimmermann M; Gross M; Slevogt H; Rieger A; Morawietz L
    Int J Surg Pathol; 2010 Oct; 18(5):330-7. PubMed ID: 20444732
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Altered expression of CD44 and DKK1 in the progression of Barrett's esophagus to esophageal adenocarcinoma.
    Darlavoix T; Seelentag W; Yan P; Bachmann A; Bosman FT
    Virchows Arch; 2009 Jun; 454(6):629-37. PubMed ID: 19396460
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CDX2, COX2 and MUC2 expressions in Barrett's esophagus: can they be useful in determination of the dysplasia?
    Türkmen IÇ; Başsüllü N; Uraz S; Yerdel MA; Memışoğlu R; Bülbül Doğusoy G
    Turk Patoloji Derg; 2012; 28(3):251-8. PubMed ID: 23011828
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CDX-2 Expression in Esophageal Biopsies Without Goblet Cell Intestinal Metaplasia May Be Predictive of Barrett's Esophagus.
    Saller J; Al Diffalha S; Neill K; Bhaskar RA; Oliveri C; Boulware D; Levine H; Kalvaria I; Corbett FS; Khazanchi A; Klapman J; Coppola D
    Dig Dis Sci; 2020 Jul; 65(7):1992-1998. PubMed ID: 31691172
    [TBL] [Abstract][Full Text] [Related]  

  • 13. COX-2, CDX2, and CDC2 immunohistochemical assessment for dysplasia-carcinoma progression in Barrett's esophagus.
    Villanacci V; Rossi E; Zambelli C; Galletti A; Cestari R; Missale G; Casa DD; Bassotti G
    Dig Liver Dis; 2007 Apr; 39(4):305-11. PubMed ID: 17307036
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tissue and serum mesothelin are potential markers of neoplastic progression in Barrett's associated esophageal adenocarcinoma.
    Rizk NP; Servais EL; Tang LH; Sima CS; Gerdes H; Fleisher M; Rusch VW; Adusumilli PS
    Cancer Epidemiol Biomarkers Prev; 2012 Mar; 21(3):482-6. PubMed ID: 22237988
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Carbonic anhydrases II, IX, and XII in Barrett's esophagus and adenocarcinoma.
    Nortunen M; Huhta H; Helminen O; Parkkila S; Kauppila JH; Karttunen TJ; Saarnio J
    Virchows Arch; 2018 Nov; 473(5):567-575. PubMed ID: 30066203
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of apoptosis-related proteins in Barrett's metaplasia-dysplasia-carcinoma sequence: a switch to a more resistant phenotype.
    van der Woude CJ; Jansen PL; Tiebosch AT; Beuving A; Homan M; Kleibeuker JH; Moshage H
    Hum Pathol; 2002 Jul; 33(7):686-92. PubMed ID: 12196918
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Altered cadherin and catenin complexes in the Barrett's esophagus-dysplasia-adenocarcinoma sequence: correlation with disease progression and dedifferentiation.
    Bailey T; Biddlestone L; Shepherd N; Barr H; Warner P; Jankowski J
    Am J Pathol; 1998 Jan; 152(1):135-44. PubMed ID: 9422531
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Disintegrin and metalloproteinases (ADAMs) expression in gastroesophageal reflux disease and in esophageal adenocarcinoma.
    Kauttu T; Mustonen H; Vainionpää S; Krogerus L; Ilonen I; Räsänen J; Salo J; Puolakkainen P
    Clin Transl Oncol; 2017 Jan; 19(1):58-66. PubMed ID: 27026568
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of bile acid transporting proteins in Barrett's esophagus and esophageal adenocarcinoma.
    Dvorak K; Watts GS; Ramsey L; Holubec H; Payne CM; Bernstein C; Jenkins GJ; Sampliner RE; Prasad A; Garewal HS; Bernstein H
    Am J Gastroenterol; 2009 Feb; 104(2):302-9. PubMed ID: 19174784
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Usefulness of insulin-like growth factor II mRNA-binding protein 3 (IMP3) as a new marker for the diagnosis of esophageal adenocarcinoma in challenging cases.
    Kazeminezhad B; Mirafsharieh SA; Dinyari K; Azizi D; Ebrahimi A
    Turk J Gastroenterol; 2014 Jun; 25(3):253-6. PubMed ID: 25141312
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.